BerGenBio ASA (BRRGF) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BerGenBio ASA announces the departure of CEO Martin Olin, who has led the company through strategic transitions and the development of its lead drug candidate, bemcentinib. The Board of Directors is now initiating a search for a new CEO to continue advancing the company’s pipeline. BerGenBio, a biopharmaceutical company focused on developing AXL inhibitors for severe diseases, remains poised for an exciting future as Olin commits to following its progress.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.